In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 5, 2022
UK Government Awards £15.9 million grant to Chemical Producer Croda
Author(s)BioPharm International Editors
UK government has awarded chemical producer Croda a £15.9 million grant to increase the UK’s capacity to manufacture key vaccine ingredients.
Advertisement
A grant of £15.9 million (approximately US$20.8 million) has been awarded to chemical producer Croda to increase the United Kingdom’s manufacturing capacity of specialty lipids, an essential ingredient in messenger RNA (mRNA) vaccines, the company announced on March 31, 2022. The grant will significantly increase Croda’s production capacity at its facility in Leek, Staffordshire.
The investment will also allow for the ability to increase both range and volume of lipid production in the UK, specifically the mRNA lipid used in numerous COVID-19 vaccines. The Leek facility will also see an increase in jobs due to the investment.
The increase in the production of mRNA lipids has the potential to transform vaccines in the future as well as further develop those existing currently. mRNA has been crucial to the production of many COVID-19 vaccines and will be able to aid in producing flu vaccines and develop new technologies such as gene therapies for cancer and heart disease.
“The development of mRNA technology has been one of the greatest scientific leaps forward since the start of the pandemic and the potential for its use in future therapies – potentially treating cancer and heart disease – is remarkable,” said Business Secretary Kwasi Kwartneg in a press release. “I am therefore extremely pleased to announce this support for Croda, a market leader in the manufacture of essential mRNA components, and the only manufacturer of lipids currently operating in the UK. Not only will this funding provide a significant boost to Britain’s life sciences industry, enabling the production of an extra 3 billion vaccine doses domestically, but it also represents an important investment into the West Midlands’ economy as we work to onshore manufacturing to the UK.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5